Unmet Needs in the Treatment of Gastroesophageal Reflux Disease

Gastroesophageal reflux disease (GERD) is a highly prevalent gastrointestinal disorder. Proton pump inhibitors have profoundly revolutionized the treatment of GERD. However, several areas of unmet need persist despite marked improvements in the therapeutic management of GERD. These include the advanced grades of erosive esophagitis, nonerosive reflux disease, maintenance treatment of erosive esophagitis, refractory GERD, postprandial heartburn, atypical and extraesophageal manifestations of GERD, Barrett’s esophagus, chronic protein pump inhibitor treatment, and post-bariatric surgery GERD. Consequently, any future development of novel therapeutic modalities for GERD (medical, endoscopic, or surgical), would likely focus on the aforementioned areas of unmet need.

• Publication year

  2015

• Venue

  Journal of Neurogastroenterology and Motility

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.5056/jnm15105PMID 26130628PMCID 4496897
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A Double-Blind, Placebo-Controlled Crossover Study With Omeprazole

  2017cited by this paper
• Obesity: Lifestyle management, bariatric surgery, drugs, and the therapeutic exploitation of gut hormones

  2015cited by this paper
• Chronic persistent cough in the adult: the spectrum and frequency of causes and successful outcome of specific therapy.

  2015cited by this paper
• Gastroesophageal Reflux Disease and Laparoscopic Sleeve Gastrectomy: A Physiopathologic Evaluation

  2014cited by this paper
• The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro‐esophageal reflux disease

  2014cited by this paper
• Laparoscopic sleeve gastrectomy in patients with preexisting gastroesophageal reflux disease : a national analysis.

  2014cited by this paper
• Consumer Use of Over-the-Counter Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease

  2014cited by this paper
• Effect of Sleeve Gastrectomy on Gastroesophageal Reflux

  2014cited by this paper
• Acid-Suppressive Therapy With Esomeprazole for Relief of Unexplained Chest Pain in Primary Care: A Randomized, Double-Blind, Placebo-Controlled Trial

  2013cited by this paper
• Is proton pump inhibitor therapy for reflux esophagitis sufficient?: a large real-world survey of Japanese patients.

  2013cited by this paper
• Step-by-step management of refractory gastresophageal reflux disease.

  2013cited by this paper
• Diagnosis and management of patients with reflux symptoms refractory to proton pump inhibitors

  2012cited by this paper
• The Role of Proton Pump Inhibitors in Gastro-oesophageal Reflux Disease

  2012cited by this paper
• Editorial: Healing Erosive Esophagitis With a Proton Pump Inhibitor: The More the Merrier?

  2012cited by this paper
• Alternative therapeutic approaches to chronic proton pump inhibitor treatment.

  2012cited by this paper
• Burden of gastrointestinal disease in the United States: 2012 update.

  2012cited by this paper
• Partial symptom‐response to proton pump inhibitors in patients with non‐erosive reflux disease or reflux oesophagitis – a post hoc analysis of 5796 patients

  2012influential reference
• Noncardiac Chest Pain: Epidemiology, Natural Course and Pathogenesis

  2011cited by this paper
• Clinical Trial: High-Dose Acid Suppression for Chronic Cough: A Randomized, Double-Blind, Placebo-Controlled Trial

  2011cited by this paper
• Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.

  2011cited by this paper
• Chronic cough and esomeprazole: A double‐blind placebo‐controlled parallel study

  2011cited by this paper
• Pharmacological management of GERD: where does it stand now?

  2011cited by this paper
• Distension of the esophagogastric junction augments triggering of transient lower esophageal sphincter relaxation.

  2011cited by this paper
• [Endoscopic management of the complications of bariatric surgery. Experience of more than 400 interventions].

  2011cited by this paper
• The lower esophageal sphincter

  2011cited by this paper
• Review article: the impact of bariatric surgery on gastrointestinal motility

  2011cited by this paper
• Nonerosive Reflux Disease (NERD) - An Update

  2010cited by this paper
• Proton pump inhibitor use is associated with an increased risk for microscopic colitis: a case–control study

  2010cited by this paper
• Management of gastroesophageal reflux disease that does not respond well to proton pump inhibitors

  2010cited by this paper
• An algorithm for diagnosis and treatment of refractory GERD.

  2010influential reference
• Increased incidence of small intestinal bacterial overgrowth during proton pump inhibitor therapy.

  2010cited by this paper
• Efficacy of Esomeprazole for Treatment of Poorly Controlled Asthma

  2010cited by this paper
• Safety of proton pump inhibitor exposure.

  2010cited by this paper
• Management of heartburn not responding to proton pump inhibitors

  2009influential reference
• Clinical course of laryngo‐respiratory symptoms in gastro‐oesophageal reflux disease during routine care ‐ a 5‐year follow‐up

  2009cited by this paper
• Treatment patterns and symptom control in patients with GERD: US community-based survey

  2009influential reference
• CLINICAL IMPLICATIONS OF CHRONIC THERAPY FOR GERD

  2009cited by this paper
• Increasing Prevalence of Erosive Esophagitis Among Taiwanese Aged 40 Years and Above: A Comparison Between Two Time Periods

  2009cited by this paper
• Efficacy of esomeprazole for treatment of poorly controlled asthma.

  2009cited by this paper
• M1041 Are Proton Pump Inhibitors (PPIs) Sufficient in Controlling Symptoms of Gastro-Esophageal Reflux Disease (GERD)? : A Community-Based US Survey Study

  2008cited by this paper
• M1033 Nighttime Symptoms and Sleep Impairment Among Patients with Gastro-Esophageal Reflux Disease (GERD) Receiving Prescription (Rx) Proton Pump Inhibitors (PPIs)

  2008cited by this paper
• Gastro-Esophageal Reflux and Esophageal Motility Disorders in Morbidly Obese Patients before and after Bariatric Surgery

  2007cited by this paper
• Medical therapy of gastroesophageal reflux disease

  2007cited by this paper
• The prevalence of and risk factors for erosive oesophagitis and non‐erosive reflux disease: a nationwide multicentre prospective study in Korea

  2007cited by this paper
• Prevalence of Upper Gastrointestinal Tract Findings in Patients With Noncardiac Chest Pain Versus Those With Gastroesophageal Reflux Disease (GERD)-Related Symptoms: Results from a National Endoscopic Database

  2007cited by this paper
• How do people with gastro-oesophageal reflux disease perceive their disease≟ Results of a multinational survey

  2007cited by this paper
• Incidence and management of marginal ulceration after laparoscopic Roux-Y gastric bypass.

  2006cited by this paper
• Proton Pump Inhibitor Therapy for Suspected GERD-Related Chronic Laryngitis: A Meta-Analysis of Randomized Controlled Trials

  2006cited by this paper
• Treatment of Chronic Posterior Laryngitis With Esomeprazole

  2006cited by this paper
• Treatment of Chronic Posterior Laryngitis With Esomeprazole

  2006cited by this paper
• Effect of Laparoscopic Gastric Banding on Esophageal Motility

  2006cited by this paper
• Proton pump inhibitor treatment of patients with gastroesophageal reflux-related chronic cough: a comparison between two different daily doses of lansoprazole.

  2006cited by this paper
• Gastrogastric Fistula: a Possible Complication of Roux-En-Y Gastric Bypass

  2006cited by this paper
• Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial.

  2006cited by this paper
• Sub‐optimal proton pump inhibitor dosing is prevalent in patients with poorly controlled gastro‐oesophageal reflux disease

  2006cited by this paper
• Long-term results and gastroesophageal reflux in a series of laparoscopic adjustable gastric banding

  2005cited by this paper
• Effect of Esomeprazole on Nighttime Heartburn and Sleep Quality in Patients with GERD: A Randomized, Placebo-Controlled Trial

  2005cited by this paper
• Gastro-oesophageal reflux treatment for prolonged non-specific cough in children and adults.

  2005cited by this paper
• The spectrum of pulmonary symptoms due to gastroesophageal reflux.

  2005cited by this paper
• Epidemiology of gastro-oesophageal reflux disease: a systematic review

  2005cited by this paper
• Esomeprazole 20 mg vs. pantoprazole 20 mg for maintenance therapy of healed erosive oesophagitis: results from the EXPO study 1

  2005cited by this paper
• Systematic review: proton‐pump inhibitor failure in gastro‐oesophageal reflux disease – where next?

  2005cited by this paper
• Prevalence, clinical spectrum and atypical symptoms of gastro‐oesophageal reflux in Argentina: a nationwide population‐based study

  2005cited by this paper
• The effect of an empirical trial of high-dose lansoprazole on symptom response of patients with non-cardiac chest pain--a randomized, double-blind, placebo-controlled, crossover trial.

  2004cited by this paper
• Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs.

  2004cited by this paper
• Risk of Clostridium difficile diarrhea among hospital inpatients prescribed proton pump inhibitors: cohort and case–control studies

  2004cited by this paper
• Noncardiac chest pain: epidemiology, natural history, health care seeking, and quality of life.

  2004cited by this paper
• Extraesophageal and atypical manifestations of GERD

  2004cited by this paper
• Heartburn severity underestimates erosive esophagitis severity in elderly patients with gastroesophageal reflux disease.

  2004cited by this paper
• Effectiveness of proton pump inhibitors in nonerosive reflux disease.

  2004influential reference
• The effect of an empirical trial of high‐dose lansoprazole on symptom response of patients with non‐cardiac chest pain – a randomized, double‐blind, placebo‐controlled, crossover trial

  2004cited by this paper
• Dietary intake and the risk of gastro-oesophageal reflux disease: a cross sectional study in volunteers

  2004cited by this paper
• Prevalence, clinical spectrum and health care utilization of gastro‐oesophageal reflux disease in a Chinese population: a population‐based study

  2003cited by this paper
• Prevalence of extra‐oesophageal manifestations in gastro‐oesophageal reflux disease: an analysis based on the ProGERD Study

  2003cited by this paper
• Nighttime heartburn is an under-appreciated clinical problem that impacts sleep and daytime function: the results of a Gallup survey conducted on behalf of the American Gastroenterological Association

  2003cited by this paper
• Non‐erosive reflux disease (NERD) — acid reflux and symptom patterns

  2003cited by this paper
• Non‐cardiac chest pain: prevalence, risk factors, impact and consulting — a population‐based study

  2003cited by this paper
• Limited (information only) patient education programs for adults with asthma.

  2002cited by this paper
• Limited (information only) patient education programs for adults with asthma.

  2002cited by this paper
• The lower esophageal sphincter.

  2002influential reference
• Gastro-oesophageal reflux disease

  2002cited by this paper
• Synergy between low‐dose ranitidine and antacid in decreasing gastric and oesophageal acidity and relieving meal‐induced heartburn

  2001cited by this paper
• Comparing lansoprazole and omeprazole in onset of heartburn relief: results of a randomized, controlled trial in erosive esophagitis patients

  2001cited by this paper
• Meta‐analysis of randomized controlled trials comparing standard clinical doses of omeprazole and lansoprazole in erosive oesophagitis

  2001cited by this paper
• Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial

  2001cited by this paper
• Patterns of proton pump inhibitor use in clinical practice.

  2001cited by this paper
• Failure of oesophageal acid control in candidates for Barrett's oesophagus reversal on a very high dose of proton pump inhibitor

  2000cited by this paper
• CHEST PAIN: PANIC ATTACK OR HEART ATTACK?

  2000cited by this paper
• Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma.

  1999influential reference
• Symptomatic gastro-oesophageal reflux disease: double blind controlled study of intermittent treatment with omeprazole or ranitidine

  1999cited by this paper
• Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification

  1999cited by this paper
• Managing cough as a defense mechanism and as a symptom. A consensus panel report of the American College of Chest Physicians.

  1998cited by this paper
• Practice guidelines on the diagnosis, surveillance, and therapy of Barrett's esophagus

  1998cited by this paper
• Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International GORD Study Group.

  1998cited by this paper
• Involvement of cholecystokininA receptors in transient lower esophageal sphincter relaxations triggered by gastric distension.

  1998cited by this paper
• Gastro‐oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole

  1998cited by this paper
• Complete elimination of reflux symptoms does not guarantee normalization of intraesophageal acid reflux in patients with Barrett's esophagus

  1998cited by this paper
• Ranitidine controls nocturnal gastric acid breakthrough on omeprazole: a controlled study in normal subjects.

  1998cited by this paper
• The clinical and economic value of a short course of omeprazole in patients with noncardiac chest pain.

  1998cited by this paper
• Does medical antireflux therapy improve asthma in asthmatics with gastroesophageal reflux?: a critical review of the literature.

  1998cited by this paper

• Effects of the Transcutaneous Electrical Stimulation System on Heartburn, Regurgitation and Esophageal Acid Exposure in GERD Patients—An Uncontrolled Feasibility Study

  2025cites this paper
• Future Opportunities for Potassium Competitive Acid Blocker in Gastroesophageal Reflux Disease and Beyond

  2025cites this paper
• Potassium-competitive acid blockers versus proton pump inhibitors: redefining the standards of care in reflux esophagitis.

  2025cites this paper
• Potassium-competitive acid blockers.

  2025cites this paper
• From erosive to non-erosive reflux disease: broadening the scope of P-CAB therapy.

  2025cites this paper
• Vonoprazan: A Review in Erosive Esophagitis and Non-Erosive Gastro-Esophageal Reflux Disease

  2025influential citation
• The Future Therapeutic Landscape of Gastroesophageal Reflux Disease

  2025cites this paper
• Economic and treatment burden among newly diagnosed patients with erosive esophagitis in the US: a national retrospective cohort study

  2025cites this paper
• Evaluation of the Efficacy and Safety of a Dual Delayed-Release Formulation of 10-mg Esomeprazole in Patients with Gastric Erosions: A Multicenter, Randomized, Double-Blind, Active-Control, Phase III Study

  2025cites this paper
• 위식도역류질환 환자에서 에소메프라졸 이중지연방출제형의 유효성과 안전성 평가: 다기관, 전향적, 비중재적 관찰연구

  2025cites this paper
• Comparison of Potassium-Competitive Acid Blockers and Proton Pump Inhibitors in Patients With Gastroesophageal Reflux Disease: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

  2024cites this paper
• Endoskopische und operative Therapie der gastroösophagealen Refluxkrankheit

  2024cites this paper
• Potassium-competitive Acid Blockers: Current Clinical Use and Future Developments

  2024cites this paper
• Revolutionizing Gastrointestinal Disorder Management: Cutting-Edge Advances and Future Prospects

  2024cites this paper
• Vonoprazan causes symptomatic improvement in non-erosive gastroesophageal reflux disease: A systematic review and meta-analysis.

  2024cites this paper
• Vonoprazan 10 mg or 20 mg vs. lansoprazole 15 mg as maintenance therapy in Asian patients with healed erosive esophagitis: A randomized controlled trial

  2024influential citation
• A translational pharmacokinetic/pharmacodynamic approach supports optimal vonoprazan dosing for erosive oesophagitis and Helicobacter pylori infection

  2023cites this paper
• Efficacy and safety of HIP1601 (dual delayed-release esomeprazole) 40 mg in erosive esophagitis compared to HGP1705 (delayed-release esomeprazole) 40 mg: a multicenter, randomized, double-blind, non-inferiority study

  2023cites this paper
• Efficacy and safety of dexlansoprazole: a comprehensive review

  2023cites this paper
• Can esophageal symptoms be associated with sleep disorders in esophageal rare diseases?. A prospective case-control study across achalasia, eosinophilic esophagitis and gastroesophageal reflux disease.

  2023cites this paper
• Carcinogenicity assessment of tegoprazan in Sprague-Dawley (Crl:CD) rats and ICR (Crl:CD1) mice.

  2023cites this paper
• Pharmacokinetics and bioequivalence study of esomeprazole magnesium enteric-coated tablets 20 mg in healthy Chinese subjects under fasting and fed conditions

  2023cites this paper
• Pharmacologic treatment of GERD in adolescents: Is esophageal mucosal protection an option?

  2022cites this paper
• Randomized controlled trial to evaluate the efficacy and safety of fexuprazan compared with esomeprazole in erosive esophagitis

  2022influential citation
• Correction of gastrocardial syndrome in patients with hernias of the esophageal orifice of the diaphragm during antireflux operations

  2022cites this paper
• GERD-related chronic cough: Possible mechanism, diagnosis and treatment

  2022cites this paper
• Patient journey in erosive oesophagitis: real-world perspectives from US physicians and patients

  2022cites this paper
• 2020 Seoul Consensus on the Diagnosis and Management of Gastroesophageal Reflux Disease

  2021cites this paper
• Acid Suppressant Therapy: a Step Forward with Potassium-Competitive Acid Blockers

  2021cites this paper
• Neue chirurgische Therapieverfahren der gastroösophagealen Refluxkrankheit und Hiatushernie

  2021cites this paper
• Osteopathic treatment in addition to standard care in patients with Gastroesophageal Reflux Disease (GERD) - A pragmatic randomized controlled trial.

  2021cites this paper
• Pharmacologic treatment of GERD: Where we are now, and where are we going?

  2020cites this paper
• Consultation with complementary medicine practitioners by individuals with chronic conditions: Characteristics and reasons for consultation in Australian clinical settings.

  2020cites this paper
• Complementary medicine practitioner consultations amongst 1,314 individuals with chronic conditions: Characteristics of users, reasons for and predictors of use.

  2020cites this paper
• Cost-effectiveness analysis of vonoprazan versus proton pump inhibitors in the treatment of reflux esophagitis in China

  2020cites this paper
• Phase III, randomised, double-blind, multicentre study to evaluate the efficacy and safety of vonoprazan compared with lansoprazole in Asian patients with erosive oesophagitis

  2019cites this paper
• In search of the grail: A race for acid suppression.

  2019cites this paper
• In search of the grail : A race for acid suppression

  2019cites this paper
• Декслансопразол МВ в лечении гастроэзофагеальной рефлюксной болезни

  2019cites this paper
• The potential role of potassium-competitive acid blockers in the treatment of gastroesophageal reflux disease.

  2019cites this paper
• Innovative Techniken in der Refluxchirurgie

  2019cites this paper
• Gastroesophageal Reflux Disease: Pathophysiology, Diagnosis, and Treatment.

  2019cites this paper
• Randomized clinical trial: a double-blind, placebo-controlled study to assess the clinical efficacy and safety of alginate–antacid (Gaviscon Double Action) chewable tablets in patients with gastro-oesophageal reflux disease

  2019cites this paper
• The Physiology of the Gastric Parietal Cell

  2019cites this paper
• In search of the grail: A race for acid suppression

  2019cites this paper
• Dexansoprazole MV in the treatment of gastroesophageal reflux disease

  2019cites this paper
• Randomised clinical trial: vonoprazan versus lansoprazole for the initial relief of heartburn in patients with erosive oesophagitis

  2019influential citation
• FRECUENCY OF BARRET'S ESOPHAGUS FOR GASTROESOPHAGEAL REFLUX IN THE CENTRAL UNIVERSITY OF VENEZUELA

  2018cites this paper
• Potent Acid Suppression with PPIs and P-CABs: What’s New?

  2018cites this paper
• The role of dexlansoprazole modified-release in the management of gastroesophageal reflux disease

  2017cites this paper
• Management of Gastroesophageal Reflux Disease.

  2017cites this paper
• History of Medical and Surgical Antireflux Therapy

  2017cites this paper
• Lower Esophageal Sphincter Augmentation for Gastroesophageal Reflux Disease: The Safety of a Modern Implant

  2017cites this paper
• Editorial: refractory GERD—good drug, wrong patients? Authors’ reply

  2017cites this paper
• Editorial: refractory GERD—good drug, wrong patients?

  2017cites this paper
• Clinical Characteristics of Patients with Untreated Achalasia

  2017cites this paper
• Sex and Gender Differences in Gastroesophageal Reflux Disease

  2016cites this paper
• Potassium-Competitive Acid Blockers (P-CABs): Are They Finally Ready for Prime Time in Acid-Related Disease?

  2015cites this paper